Patents by Inventor Jeffrey A. Hubbell

Jeffrey A. Hubbell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10821157
    Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: November 3, 2020
    Assignees: ANOKION SA, ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (“EPFL”)
    Inventors: Jeffrey A. Hubbell, Stephane Kontos, Kristen Marie Lorentz, David Scott Wilson, Shuning Gai
  • Patent number: 10800838
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: October 13, 2020
    Assignee: École Polytechnique Fédérale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Patent number: 10711106
    Abstract: The present invention features linear and three-dimensional supramolecular materials self-assembled from block co-polymers comprising oligo(ethylene sulfide) (OES). The block copolymers assemble into fibrils, micelles, or matrices. The fibrillar materials are sensitive to oxidation, which leads to decreased OES block hydrophobicity and crystallinity, and increased water solubility of the polymer constituents. Molecular loading options, coupled with oxidative sensitivity, allow implantable or injectable fibrillar suspensions or cross-linked three-dimensional matrices to demonstrate significant biomedical potential, especially in the context of extracellular and intracellular molecular delivery and applications related to infection and disease.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: July 14, 2020
    Assignee: The University of Chicago
    Inventors: Jeffrey A. Hubbell, Carrie E. Brubaker, Diana Velluto
  • Patent number: 10660987
    Abstract: Hydrodynamic methods for conformally coating non-uniform size cells and cell clusters for implantation, thus preventing immune rejection or inflammation or autoimmune destruction while preserving cell functionality. A method for conformally coating cells and c clusters with hydrogels that are biocompatible, mechanically and chemically stable and porous, with an appropriate pore cut-off size. The methods of the invention are advantageously reproducible and result in a relatively high yield of coated versus non-coated cell clusters, without compromising cell functionality. Conformal coating devices configured to perform the methods of the invention, methods of optimally utilizing said devices and purifying the coated islets, and coated biomaterials made by said methods.
    Type: Grant
    Filed: April 28, 2012
    Date of Patent: May 26, 2020
    Assignee: CONVERGE BIOTECH INC.
    Inventors: Jeffrey Hubbell, Alice Tomei
  • Patent number: 10653816
    Abstract: Hydrodynamic methods for conformally coating non-uniform size cells and cell clusters for implantation, thus preventing immune rejection or inflammation or autoimmune destruction while preserving cell functionality. A method for conformally coating cells and cell clusters with hydrogels that are biocompatible, mechanically and chemically stable and porous, with an appropriate pore cut-off size. The methods of the invention are advantageously reproducible and result in a relatively high yield of coated versus non-coated cell clusters, without compromising cell functionality. Conformal coating devices configured to perform the methods of the invention, methods of optimally utilizing said devices and purifying the coated islets, and coated biomaterials made by said methods.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: May 19, 2020
    Assignee: CONVERGE BIOTECH INC.
    Inventors: Jeffrey Hubbell, Alice Tomei
  • Publication number: 20200129601
    Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 30, 2020
    Inventors: Jeffrey A. Hubbell, David Scott Wilson
  • Publication number: 20200129625
    Abstract: Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. In several embodiments, the compositions are configured for clearance of a circulating protein or peptide or antibody associated with one or more of the above-mentioned maladies. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 30, 2020
    Inventors: Jeffrey A. Hubbell, David Scott Wilson
  • Publication number: 20200129629
    Abstract: Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 30, 2020
    Inventors: Jeffrey A. Hubbell, David Scott Wilson
  • Publication number: 20200123228
    Abstract: The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with an antibody that is specifically targeted to and/or retained intra- or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide. An ECM-affinity peptide is one that has affinity for an extracellular matrix protein.
    Type: Application
    Filed: April 20, 2018
    Publication date: April 23, 2020
    Inventors: Jeffrey A. HUBBELL, Jun ISHIHARA, Ako ISHIHARA, Kazuto FUKUNAGA, Melody SWARTZ
  • Publication number: 20200121762
    Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 23, 2020
    Inventors: Jeffrey A. Hubbell, Stephane Kontos, Kristen Marie Lorentz, David Scott Wilson, Shuning Gai
  • Publication number: 20200101169
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Application
    Filed: September 26, 2019
    Publication date: April 2, 2020
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Publication number: 20200101146
    Abstract: Several embodiments provided in the present disclosure relate to compositions that carry an antigen to which tolerance is desired, the antigen being coupled, bound, or otherwise joined to a targeting moiety, the targeting moiety configured to direct the composition to the liver of a subject. In several embodiments, the antigen in coupled to the targeting moiety by way of a polymeric linker. In several embodiments, the polymeric linker is configured to liberate the antigen in vivo. Methods of using the compositions to reduce and/or prevent unwanted immune responses against an antigen of interest are also provided.
    Type: Application
    Filed: June 14, 2018
    Publication date: April 2, 2020
    Inventors: Jeffrey A. Hubbell, David Scott Wilson, Kristen Marie Lorentz, Stephan Kontos
  • Publication number: 20200048390
    Abstract: Provided herein are polymer materials that find use in, for example, delivery of short-chain fatty acids. In particular, polymers are provided that form stable nanoscale structures and release their payload, for example, by cleavage of a covalent bond (e.g., via hydrolysis or enzymatic cleavage). The polymers are useful, for example, for delivery of payloads (e.g., SCFAs) to the intestine for applications in health and treatment of disease, and have broad applicability in diseases linked to changes in the human microbiota including inflammatory, autoimmune, allergic, metabolic, and central nervous system diseases, among others.
    Type: Application
    Filed: April 17, 2018
    Publication date: February 13, 2020
    Inventors: Jeffrey A. Hubbell, Ruyi Wang, D. Scott Wilson, Cathryn R. Nagler, Catherine Plunkett
  • Publication number: 20200000936
    Abstract: An encoding/decoding apparatus and method using a low-density parity-check code (LDPC code) is disclosed. Basic column group information, serving as a set of information regarding positions of rows with weight 1, is extracted from a reference column in each column group of a predetermined parity-check matrix. Column group information transforms the positions of rows with weight 1 into positions whose lengths are within a required parity length. A parity-check matrix is generated according to the generated column group information. Data is enclosed or decoded based on the generated parity-check matrix.
    Type: Application
    Filed: July 1, 2019
    Publication date: January 2, 2020
    Inventors: James Brandon DIXON, Jeffrey A. Hubbell, Conlin P. O'Neil, Melody Swartz, Diana Velluto
  • Publication number: 20190382479
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.
    Type: Application
    Filed: July 26, 2019
    Publication date: December 19, 2019
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Patent number: 10471155
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: November 12, 2019
    Assignee: École Polytechnique Fédérale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Patent number: 10392437
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: August 27, 2019
    Assignee: École Polytechnique Fédérale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Patent number: 10335499
    Abstract: Block copolymers containing charged blocks or chemical moieties sensitive to oxidation or hydrolysis have been developed. We describe the use of such block copolymers in supramolecular structures, e.g., micelles or vesicles, and pharmaceutical compositions and in methods of preparing the supramolecular structures and pharmaceutical compositions. The invention is particularly useful for the delivery of pharmaceutical agents, e.g., nucleic acids, to cells.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: July 2, 2019
    Assignee: École Polytechnique Fédérale de Lausanne (EPFL)
    Inventors: James Brandon Dixon, Jeffrey A. Hubbell, Conlin P. O'Neil, Melody Swartz, Diana Velluto
  • Publication number: 20190117838
    Abstract: The invention relates to methods for producing a polymeric scaffold for use in tissue engineering applications or soft tissue surgery, as wellto the produced scaffolds and an associated kit. The method features a first fast drying step of applying a as mechanical compression on a polymeric gel layer and a second slow drying step of the gel up to reach a polymer mass fraction of at least 60% w/w in the final scaffold. The method allows the production of scaffolds with high regeneration and healing properties of a grafted tissue via host cell invasion and colonization, and a good suturability. These goals are achieved through the formation within the scaffold of a non-uniform architecture creating softer and stiffer areas, which is maintained even upon re-swelling of the scaffold upon hydration of the final dried product.
    Type: Application
    Filed: March 29, 2017
    Publication date: April 25, 2019
    Inventors: Peter FREY, Jeffrey A. HUBBELL, Hans M. LARSSON, Elif VARDAR, Eva-Maria BALET, Ganesh VYTHILINGHAM, Kalitha PINNAGODA
  • Patent number: 10265415
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: April 23, 2019
    Assignee: École Polytechnique Fédérale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane